Anal cancer: An HIV-associated cancer

Hematology/Oncology Clinics of North America

Volumn 17, Issue 3, 2003, Pages 859-872

  Klencke, Barbara J ^a,b   Palefsky, Joel M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANUS CANCER; CANCER CYTODIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CARCINOMA IN SITU; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RECTUM BIOPSY; REVIEW; TREATMENT PLANNING; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 0038386836     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00039-X     Document Type: Review

References (64)

1. Beckmann AM, Daling JR, Sherman KJ, et al. Human papillomavirus infection and anal cancer. Int J Cancer 1989;43(6):1042-9.
2. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87(11):796-802.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.
4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7-33.
5. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989;81(22):1726-31.
6. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337(19):1350-8.
7. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol 1994;139(8):772-80.
8. Melbye M, Cote TR, Kessler L, Gail M, Biggar RJ. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994;343(8898):636-9.
9. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285(13):1736-45.
10. Tilston P. Anal human papillomavirus and anal cancer. J Clin Pathol 1997;50(8):625-34.
11. Schiffman MH. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol 1994;186:55-81.
12. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995;76(Suppl 10):1888-901.
13. Caussy D, Goedert JJ, Palefsky J, et al. Interaction of human immunodeficiency and papilloma viruses: association with anal epithelial abnormality in homosexual men. Int J Cancer 1990;46(2):214-9.
14. Kiviat N, Rompalo A, Bowden R, et al. Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men. J Infect Dis 1990;162(2):358-61.
15. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998;12(5):495-503.
16. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-I (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999;91(3):226-36.
17. Williams AB, Darragh TM, Vranizan K, Ochia C, Moss AR, Palefsky JM. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994;83(2):205-11.
18. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr 1998;17(4):314-9.
19. Critchlow CW, Hawes SE, Kuypers JM, et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 1998;12(10):1177-84.
20. Critchlow CW, Surawicz CM, Holmes KK, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995;9(11):1255-62.
21. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001;93(11):843-9.
22. Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001;28(5):422-8.
23. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM, Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000;108(8):634-41.
24. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;281(19):1822-9.
25. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Hogeboom CJ, Darragh TM. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med 1997;73(3):174-80.
26. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum 1997;40(8):919-28.
27. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002;35(9):1127-34.
28. Weiss EG, Wexner SD. Surgery for anal lesions in HIV-infected patients. Ann Med 1995;27(4):467-75.
29. Nadal SR, Manzione CR, Galvao VM, Salim VR, Speranzini MB. Healing after anal fistulotomy: comparative study between HIV+ and HIV- patients. Dis Colon Rectum 1998;41(2):177-9.
30. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 2002;45(4):453-8.
31. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8(5):1028-37.
32. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121(2):216-25.
33. Palefsky JM, Goldstone SE, Neefe JR. HspE7 treatment of high-grade anal dysplasia: final results of an open-label trial and interim long term follow-up. Presented at the 20th International HPV Conference. Paris, France, October 4-9, 2002.
34. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 2002;45(4):502-7.
35. Myerson RJ, Karnell LH, Menck HR. The National Cancer Database report on carcinoma of the anus. Cancer 1997;80(4):805-15.
36. Beahrs OH, Wilson SM. Carcinoma of the anus. Ann Surg 1976;184(4):422-8.
37. Singh R, Nime F, Mittelman A. Malignant epithelial tumors of the anal canal. Cancer 1981;48(2):411-5.
38. Schneider TC, Schulte WJ. Management of carcinoma of anal canal. Surgery 1981;90(4):729-34.
39. Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer 2001;92(1):77-84.
40. Tarantino D, Bernstein MA. Endoanal ultrasound in the staging and management of squamous-cell carcinoma of the anal canal: potential implications of a new ultrasound staging system. Dis Colon Rectum 2002;45(1):16-22.
41. Whiteford MH, Stevens Jr KR, Oh S, Deveney KE. The evolving treatment of anal cancer: how are we doing? Arch Surg 2001;136(8):886-91.
42. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000;342(11):792-800.
43. Esiashvili N, Landry J, Matthews RH. Carcinoma of the anus: strategies in management. Oncologist 2002;7(3):188-99.
44. UKCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348(9034):1049-54.
45. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15(5):2040-9.
46. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14(9):2527-39.
47. Myerson RJ, Kong F, Birnbaum EH, et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol 2001;61(1):15-22.
48. Allal AS, Mermillod B, Roth AD, Marti MC, Kurtz JM. Impact of clinical and therapeutic factors on major late complications after radiotherapy with or without concomitant chemotherapy for anal carcinoma. Int J Radiat Oncol Biol Phys 1997;39(5):1099-105.
49. Cummings BJ, Keane TJ, O'Sullivan B, Wong CS, Carton CN. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991;21(5):1115-25.
50. Touboul E, Schlienger M, Buffat L, et al. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 1994;73(6):1569-79.
51. Wagner JP, Mahe MA, Romestaing P, et al. Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1994;29(1):17-23.
52. Chadha M, Rosenblatt EA, Malamud S, Pisch J, Berson A. Squamous-cell carcinoma of the anus in HIV-positive patients. Dis Colon Rectum 1994;37(9):861-5.
53. Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology 1994;193(1):251-4.
54. Hocht S, Wiegel T, Kroesen AJ, Berdel WE, Runkel N, Hinkelbein W. Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection. Acta Oncol 1997;36(8):799-802.
55. Peddada AV, Smith DE, Rao AR, Frost DB, Kagan AR. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1997;37(5):1101-5.
56. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999;44(1):127-31.
57. Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum 2001;44(10):1496-502.
58. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum 2001;44(4):506-12.
59. Cleator S, Fife K, Nelson M, Gazzard B, Phillips R, Bower M. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 2000;36(6):754-8.
60. Muderspach L, Wilczynski S, Roman C, Blade L, Felix J, Small LA, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV-16 positive. Clin Cancer Res 2000;6:3406-16.
61. Peiffert D, Giovannini M, Ducreux M, Michael P, Francois E, Lemanski L, et al. High-dose radiation therapy and neoadjuvant plus con comitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal cancer: final results of a phase II study. Ann Oncol 2001;12:397-404.
62. Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, Lozzy L. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer for the anus: result in 35 consecutive patients. J Clin Oncol 1996;14:3121-5.
63. Martenson JA, Lipsitz SR, Wagner Jr H, Kaplan EH, Otteman LA, Schuchter LM, et al. Initial results of a phase II trail of high dose radiation therapy, 5-flurouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys 1996;35:745-9.
64. Rich TA, Ajani JA, Morrison WH, Ota D, Levin B. Chemo radiation therapy for anal cancer: radiation plus continuous infusion of 5-fluosouracil with or without cisplatin. Radiother Oncol 1993;27:209-15.